N: Quote, Profile, Research) a royalty on sales of its generic version of J&J's painkiller Ultracet, ending litigation between the two companies. ...
Par Pharmaceutical Cos. and Ortho-McNeil Pharmaceutical Inc. have settled a patent infringement case regarding Ortho-McNeil’s Ultracet pain medication. ...
Ultracet is indicated for the short-term management of acute pain. PS PRX has received a PowerRating of 7. TradingMarkets PowerRatings are a proprietary ...
As part of the settlement, Par/Kali acknowledged that the reissue patent for ULTRACET is valid and enforceable, and that they infringed it by selling ...
Par received approval from the US Food and Drug Administration and began marketing its generic version of Ultracet(R) in April 2005. ...
J&J, the second-biggest US drug maker, sued Par in August 2006 in federal court in Newark to force it to stop selling generic Ultracet. ...
Par Pharmaceutical Cos. and Ortho-McNeil Pharmaceutical Inc. have settled a patent infringement case regarding Ortho-McNeil's Ultracet pain medication. ...
all 43 news articles
... agreement with Ortho-McNeil Pharmaceutical Inc. , ending a patent suit related to the Johnson & Johnson (JNJ) unit's Ultracet acute pain product. ...
The settlement includes Par entering into a consent judgment that the patent for Ultracet is valid and enforceable.